Microencapsulated CYP 2B1-expressing cells - PharmaCyte Biotech

Drug Profile

Microencapsulated CYP 2B1-expressing cells - PharmaCyte Biotech

Alternative Names: Breast cancer cell therapy - PharmaCyte Biotech; CypCaps; Encapsulated cyclophosphamide-activating cells - PharmaCyte Biotech; Encapsulated ifosfamide-activating cells - PharmaCyte Biotech; NovaCaps®; Ovarian cancer cell therapy - PharmaCyte Biotech; Pancreatic cancer cell therapy - PharmaCyte Biotech

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Austrianova; SG Austria
  • Developer PharmaCyte Biotech; Translational Drug Development
  • Class Cell therapies; Chemoprotectants; Gene therapies
  • Mechanism of Action Cytochrome P-450 enzyme system stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Preclinical Breast cancer; Malignant ascites; Ovarian cancer
  • Research Pain

Most Recent Events

  • 24 Nov 2017 Preclinical development is ongoing for Breast cancer in USA (Pharmacyte Biotech pipeline, November 2017)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral, Implant)
  • 21 Mar 2017 PharmaCyte Biotech files for provisional patent protection with the United States Patent and Trademark Office for microencapsulated CYP 2B1-expressing cells
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top